Wockhardt net profit jumps over 11-fold to Rs 37.17 crore in Q2
New Delhi: Drug firm Wockhardt on Monday reported an over 11-fold jump in its consolidated net profit to Rs 37.17 crore for the quarter ended September 30, 2021.The company had posted a net profit of Rs 3.29 crore for the corresponding period of the previous fiscal, Wockhardt said in a regulatory filing.Consolidated revenue of the company stood at Rs 862 crore for the quarter under...
New Delhi: Drug firm Wockhardt on Monday reported an over 11-fold jump in its consolidated net profit to Rs 37.17 crore for the quarter ended September 30, 2021.
The company had posted a net profit of Rs 3.29 crore for the corresponding period of the previous fiscal, Wockhardt said in a regulatory filing.
Consolidated revenue of the company stood at Rs 862 crore for the quarter under consideration. It was Rs 714.05 crore in the year ago period, it added.
"Net debt-equity ratio as on September 30, 2021, stood at 0.54." the filing said.
The UK business grew by 66 per cent over the previous corresponding quarter and stood at Rs 387 crore in Q2FY22.
It contributed about 45 per cent of the global revenue, it added.
The continuing India business stood at Rs 187 crore in the second quarter of FY22 registering growth of 47 per cent.
It contributed 22 per cent of the global revenue, Wockhardt said.
"Research and development expenditure during the quarter was at Rs39 crore (5 per cent to sales) and including capital expenditure was at 7.4 per cent to sales," it added.
Read also: Wockhardt, RDIF collaborate for producing Sputnik V, Sputnik Light
Three patents were filed during the quarter ended September 30, 2021, and the cumulative filings till date are 3,194.
The company was granted 4 patents during the quarter and now holds 770 patents, Wockhardt said.
Shares of Wockhardt were trading at Rs 464.30 per scrip on BSE, up 5.43 per cent from its previous close.
Read also: Wockhardt, Jemincare tie up for respiratory antibiotic Nafithromycin
Wockhardt is an Indian Multi-National Company headquartered in Mumbai. It has 3 research centres and 12 manufacturing plants, with businesses ranging from the manufacture and marketing of Pharmaceutical and Bio-pharmaceutical formulations, Active Pharmaceutical Ingredients (APIs) and Vaccines.
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd